Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

Fig. 1

Free NAT, cell-bound NAT and VLA-4 expression levels in regular NAT-treated patients. Free NAT concentration (a, b), cell-bound NAT on CD3 cells (c,d) and VLA-4 expression level in CD3 cells (e,f) of NAT-treated (NAT; black circle) and untreated (non-NAT; black triangle) patients with MS were determined in blood (left) and CSF (right). One year later (after 12 more NAT infusions), 13 NAT-treated patients with MS were re-analysed (NAT + 1a; black square). NAT values in blood were determined before (NAT Pre) and 20 min after (NAT Post) NAT infusion. **p < 0.01, ***p < 0.001

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094